Retatrutide: The Triple Agonist
The most effective weight loss peptide ever studied — 24.2% body weight reduction in Phase 2 trials via simultaneous GLP-1, GIP, and glucagon receptor activation.
24.2%
Weight loss — Phase 2
3
Receptor targets
#1
Highest clinical trial result
GLP-1+GIP+GCG
Mechanism
What Makes Retatrutide Different
Every receptor adds a distinct, complementary mechanism. The three-receptor combination produces effects impossible with single or dual agonists.
Appetite reduction
GLP-1 receptor activation suppresses hunger signals in the hypothalamus, slows gastric emptying, and reduces caloric intake — the mechanism shared by semaglutide and tirzepatide.
Direct fat cell action + insulin sensitivity
GIP receptors are expressed directly on adipocytes. GIP agonism reduces fat storage and increases insulin sensitivity independently of appetite suppression — the mechanism added by tirzepatide.
Fat oxidation + thermogenesis + liver fat burning
Glucagon receptor activation increases energy expenditure via thermogenesis, promotes hepatic fat oxidation (making it uniquely effective for NASH), and stimulates lipolysis directly. At GLP-1-balanced doses, muscle is preserved because the GLP-1 component offsets glucagon's catabolic and hyperglycemic tendency.
Phase 2 Trial Results
Phase 3 (TRIUMPH-3) ongoing. Results anticipated 2026–2027.
Clinical Weight Loss Comparison
Sema: STEP-1 (68 wks) · Tirz: SURMOUNT-1 (72 wks) · Reta: Phase 2 (48 wks)
Dosing Protocol
Retatrutide follows the same slow titration approach as other GLP-1 agents — starting low to minimize GI side effects before stepping up. Most users report excellent results at the 4–8mg range without needing to reach the maximum 12mg dose.
Standard Titration Schedule
Starting dose — tolerance establishment
Most users reach therapeutic effect here
Intermediate dose — excellent results
Maximum dose — Phase 2 peak efficacy
Most users find their sweet spot at 4–8mg. Escalate only if needed.
Who Should Choose Retatrutide
Retatrutide is not the default starting point — it's the escalation for those who need more than semaglutide or tirzepatide can deliver.
Experienced GLP-1 users looking for maximum efficacy beyond tirzepatide
People with NASH or fatty liver disease needing hepatic fat reduction
Those who have plateaued on tirzepatide and need a next step
People prioritizing metabolic and cardiovascular outcomes alongside weight loss
Users seeking the lowest achievable body weight floor based on clinical data
Retatrutide Products
Choose the vial size that fits your protocol.
How Retatrutide Compares
A quick snapshot of where retatrutide sits in the GLP-1 class.
vs Semaglutide
+9.3%
More weight loss. Adds GIP and glucagon receptor mechanisms.
vs Tirzepatide
+1.7%
Modest additional weight loss, but adds glucagon-driven thermogenesis and liver benefits.
vs Class Average
Best in class
No compound in any clinical trial has produced greater mean body weight reduction.
Retatrutide FAQ
What is retatrutide?
Retatrutide is a triple receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. It is the most efficacious weight loss compound ever studied in clinical trials, achieving 24.2% mean body weight loss over 48 weeks in Phase 2 data. It is currently in Phase 3 development.
Retatrutide vs Tirzepatide — which is better?
Retatrutide produces greater weight loss (24.2% vs 22.5%) and adds glucagon receptor activation, which drives thermogenesis and liver fat oxidation beyond what tirzepatide achieves. However, tirzepatide has more mature Phase 3 data (SURMOUNT-1, 72 weeks) and a longer clinical track record. For pure efficacy, retatrutide leads. For validated long-term data, tirzepatide is currently ahead.
What are the retatrutide side effects?
The most common side effects in Phase 2 trials were nausea, vomiting, diarrhea, and constipation — consistent with the GLP-1 drug class. These were dose-dependent and most frequent during titration. Unlike some glucagon agonists used in isolation, retatrutide did not significantly raise blood glucose because the GLP-1 component offsets glucagon's hyperglycemic tendency.
Is retatrutide approved by the FDA?
No. As of 2026, retatrutide is in Phase 3 clinical trials and has not received FDA approval. It is available for research purposes. Phase 3 data is anticipated in 2026–2027, with a potential NDA submission to follow.
Related Reading